Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $19.50 Average PT from Brokerages

Shares of Benitec Biopharma Inc. (NASDAQ:BNTC) have been given a consensus rating of “Buy” by the six analysts that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $22.60.

A number of research firms have recently commented on BNTC. Guggenheim began coverage on shares of Benitec Biopharma in a research report on Thursday, September 12th. They set a “buy” rating and a $17.00 price target for the company. Oppenheimer began coverage on shares of Benitec Biopharma in a research report on Wednesday, October 16th. They set an “outperform” rating and a $35.00 price target for the company. Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a research report on Friday. Leerink Partnrs upgraded shares of Benitec Biopharma to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Leerink Partners began coverage on shares of Benitec Biopharma in a research report on Monday, July 22nd. They set an “outperform” rating and a $13.00 price target for the company.

Benitec Biopharma Trading Down 3.6 %

Benitec Biopharma stock opened at $10.69 on Wednesday. Benitec Biopharma has a 1-year low of $2.69 and a 1-year high of $12.89. The firm has a market capitalization of $100.14 million, a price-to-earnings ratio of -5.60 and a beta of 0.90. The firm has a 50 day simple moving average of $9.27 and a 200 day simple moving average of $8.48.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTC. Nantahala Capital Management LLC purchased a new position in Benitec Biopharma in the second quarter worth $5,881,000. Janus Henderson Group PLC grew its position in Benitec Biopharma by 35.5% in the first quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 64,092 shares in the last quarter. Simplify Asset Management Inc. purchased a new position in Benitec Biopharma in the second quarter worth $358,000. Finally, GAMMA Investing LLC grew its position in Benitec Biopharma by 53.0% in the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 1,884 shares in the last quarter. 52.19% of the stock is currently owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.